Received Mar 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
HCP reported an adult patient missed their 3rd scheduled dose of GARDASIL9. HCP stated the 2nd dose was received over a year ago. Specific date of administration was not provided. Patient demographics were not provided. No additional information was; No additional AE; This spontaneous report was received from a Nurse regarding an Adult patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On an unknown date, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection. On an unknown date in 2024 (also reported as over a year ago), the patient was vaccinated with the second dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9), Injection; both doses were administered as prophylaxis (exact dose, route of administration, anatomical site of injection, lot number and expiration date were not reported for any of the mentioned vaccines). On an unknown date, the patient missed their 3rd schedule dose of the Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) vaccine (Inappropriate schedule of product administration). No additional adverse event was reported for the patient.